Table 5. Potential treatment targets through ClinVar in GEPNEC.

Target genes	No.	Drugs
GEPNEC, gastroenteropancreatic neuroendocrine carcinoma; Genes associated with target therapy were listed binding to the applications of potential drugs. Drugs were approved by Food and Drug Administration (FDA) or used in phase III clinical trial.
BRAF V600E (mutation)	2	Vemurafenib, Dabrafenib, Encorafenib
MET (amplification)/ ALK (fusion)	2	Crizotinib, Lorlatinib, Ceritinib, Alectinib, Brigatinib
KRAS G12C (mutation)	1	Sotorasib, Adagrasib, JNJ-74699157, GDC-6036, LY3499446, JDQ443, D-1553
RET (fusion)	2	Selpercatinib, Pralsetinib, Cabozantinib, Vandetanib, TPX-0046, RXDX-105, BOS172738
PIK3CA E545K (mutation)	1	Everolimus, Temsirolimus, Alpelisib, Copanlisib, Taselisib, CYH33, TQ-B3525, BKM120, Inavolisib, SF1126, GDC-0084, Copanlisib hydrochloride
CDK4/ CDK6 (amplification)	1	Palbociclib, Ribociclib, Abemaciclib, SHR6390, PD 0332991, Trilaciclib, G1T38, LEE011
CDH1 (mutation)	1	Crizotinib, Savolitinib, Capmatinib, Tepotinib, ARQ 197
BRCA12, ATM and ATR (germline mutation)	3	Olaparib, Rucaparib, Niraparib, Talazoparib
MSI-H	3	Pembrolizumab, Nivolumab, Ipilimumab, Tislelizumab, Sintilimab, Toriplimab, Camrelizumab, Envafolomab
TMB-H	16